Search our Database of Scientific Publications and Authors

I’m looking for a

    1582 results match your criteria Hidradenitis Suppurativa

    1 OF 32

    Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity.
    Br J Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité University Medicine, Berlin, Germany.
    Background: A validated tool for the dynamic severity assessment of hidradenitis suppurativa (HS) is lacking. The aim of this study was to develop and validate such a novel scoring system.

    Methods: A Delphi voting procedure was conducted among the members of the European Hidradenitis Suppurativa Foundation (EHSF) to achieve consensus towards an initial HS Severity Score System (HS4). Read More

    Hidradenitis Suppurativa in Down Syndrome: A Case Series.
    Pediatr Dermatol 2017 Jun 21. Epub 2017 Jun 21.
    King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
    Background/objectives: Many dermatologic and systemic diseases have been reported in association with hidradenitis suppurativa, but its association with Down syndrome is rarely mentioned in the literature. The objective of the current study was to assess the frequency of hidradenitis suppurativa in patients with Down syndrome who visited our clinic over 4 years.

    Methods: We recorded the presenting complaints and dermatologic problems of patients with Down syndrome who visited our clinic from January 2011 to December 2014. Read More

    The microRNA effector RNA-induced silencing complex in hidradenitis suppurativa: a significant dysregulation within active inflammatory lesions.
    Arch Dermatol Res 2017 Jun 20. Epub 2017 Jun 20.
    Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.
    Recently, we could show that the expression levels of the key regulators of the microRNA (miRNA) maturation and transport were dysregulated in inflamed hidradenitis suppurativa (HS) tissue (Heyam et al. in Wiley Interdiscip Rev RNA 6:271-289, 2015). The RNA-induced silencing complex (RISC) is the central element of the miRNA pathway and regulates miRNA formation and function. Read More

    Examining the race-specific prevalence of hidradenitis suppurativa at a large academic center; results from a retrospective chart review.
    Dermatol Online J 2017 Jun 15;23(6). Epub 2017 Jun 15.
    Department of Dermatology, University of Cincinnati, Cincinnati, Ohio.
    Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating disease of unknown etiology. HS can occur in people of all ethnicities and ages, and affects approximately 3-4% of the United States. To date, few studies have specifically examined the race prevalence of HS; further epidemiological research is needed to identify specific trends among HS and its racial predilections. Read More

    PASH syndrome a disease with genetic heterogeneity.
    Br J Dermatol 2017 Jun 18. Epub 2017 Jun 18.
    Department of Dermatology and Venereology, University Hospital of Brest.
    PASH syndrome is a clinical entity associating pyoderma gangrenosum (PG), severe acne and hidradenitis suppurativa (HS)(1) . Absence of pyogenic sterile arthritis (PA) distinguishes PASH syndrome from PAPASH and PAPA syndromes which associate PA in combination with PG, severe acne with or without HS, respectively(2,3) . Mutations in PSTPIP1 (proline-serine-threonine-phosphatase interacting protein 1) gene were identified in patients with PAPA and PAPASH syndromes, although genetic heterogeneity was observed in PAPA syndrome(2,3) . Read More

    Oral ofloxacin and clindamycin as an alternative to the classic rifampicin/clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients.
    Br J Dermatol 2017 Jun 18. Epub 2017 Jun 18.
    Department of Dermatology, Edouard Herriot Hospital, Claude Bernard Lyon I University, Lyon, France.
    Rifampicin/Clindamycin (RC) combination is recommended as first line therapy in moderate to severe Hidradenitis Suppurativa (HS) by European S1 guidelines (1-3), notably because a large variety of microorganisms have been isolated from HS lesions: most represented bacteria appear to be Staphylococcus aureus, Coagulase negative staphylococci (CoNS) and anaerobic bacteria from normal skin flora. It has been hypothesized that these bacteria could play a central role in the initiation and maybe in the maintenance of HS lesions, possibly by being a source of antigens in a dysregulated immune response. This article is protected by copyright. Read More

    35-Year Experience with Surgical Treatment of Hidradenitis Suppurativa.
    World J Surg 2017 Jun 13. Epub 2017 Jun 13.
    University of Michigan, TC 2124 University Hospital SPC 5343, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.
    Background: Hidradenitis suppurativa is a painful and disfiguring chronic inflammatory condition affecting both men and women. Medical treatments, such as antibiotics and immunosuppressive agents, are often ineffective. Over time, patients can suffer from recurrent abscesses, chronic purulent drainage, scarring, and contractures that can only be corrected by surgical excision. Read More

    Botulinum Toxin Off-Label Use in Dermatology: A Review.
    Skin Appendage Disord 2017 Mar 1;3(1):39-56. Epub 2017 Feb 1.
    Dermatology Unit, Department of Clinical and Molecular Sciences, United Hospital of Ancona, Polytechnic Marche University, Ancona, Italy.
    Background: Botulinum toxin is a neurotoxin produced by the bacterium Clostridium botulinum which causes a flaccid muscle paralysis. It is currently used for aesthetic treatments and in the focal hyperhidrosis. Recently, botulinum toxin has also been used experimentally in many other dermatological conditions with good results. Read More

    The Burden of Hidradenitis Suppurativa in a Cohort of Patients in Southern Finland: A Pilot Study.
    Skin Appendage Disord 2017 Mar 12;3(1):20-27. Epub 2017 Jan 12.
    Department of Dermatology and Allergology, AbbVie Oy, Espoo, Finland.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that impacts the quality of life.

    Methods: We evaluated its burden in a cohort of 26 Finnish patients in a single-center cross-sectional study. Demographic data, disease history, clinical data, treatment patterns, and workability were collected. Read More

    Optimal Wound Care Management in Hidradenitis Suppurativa.
    J Dermatolog Treat 2017 Jun 13:1-11. Epub 2017 Jun 13.
    a Department of Dermatology , Johns Hopkins School of Medicine , Baltimore , United States of America.
    Hidradenitis suppurativa (HS) presents the problem of a chronic, relapsing, painful, draining wound. There is a myriad of HS wound care management strategies implemented by clinicians and patients that is centered around which dressings to use. Many factors affect which HS wound care dressing is the most appropriate to use such as the type of HS wound, cost, ease of application, patient comfort, absorbency, and odor management among many others. Read More

    Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa.
    J Dermatolog Treat 2017 Jun 13:1-40. Epub 2017 Jun 13.
    c Adelphi Values USA , Boston , Massachusetts , USA.
    Background: Two patient-reported outcome (PRO) questionnaires, the Hidradenitis Suppurativa Symptom Assessment (HSSA) and Hidradenitis Suppurativa Impact Assessment (HSIA), were developed to measure signs, symptoms, and impacts of HS in treatment efficacy studies.

    Methods: In accordance with FDA guidelines and published best practices, four stages of research were conducted to create the questionnaires: concept elicitation, questionnaire construction, content evaluation, and psychometric evaluation.

    Results: Subjects (N = 20) who participated in the concept elicitation stage reported 15 unique HS-related signs and symptoms and 51 impacts. Read More

    Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa.
    J Eur Acad Dermatol Venereol 2017 Jun 11. Epub 2017 Jun 11.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
    Background: Hidradenitis suppurativa (HS) is a recalcitrant chronic skin disease with poorly understood immunopathogenic mechanisms. Previous studies reported that the interleukin-36 (IL-36) cytokines (IL-36α, IL-36β, IL-36γ, and IL-36 receptor antagonist [IL-36RA]) are important players in the pathogenesis of psoriasis (PS).

    Objective: We aim to determine whether the IL-36 cytokines are upregulated in HS patients. Read More

    Comment on: "Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study".
    Am J Clin Dermatol 2017 Jun 8. Epub 2017 Jun 8.
    Department of Dermatology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), C/ Maestro Alonso s/n, 03010, Alicante, Spain.

    Thyroid autoimmunity in patients with hidradenitis suppurativa: a case-control study.
    Clin Exp Dermatol 2017 Jun 7. Epub 2017 Jun 7.
    Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Cantabria, Spain.
    The aetiopathogenesis of hidradenitis suppurativa (HS) is not fully understood; however, increasing evidence suggests that it may be an immune-mediated disorder. Autoimmune thyroid disease (AITD) has classically been considered as the 'paradigm' of autoimmunity, and it has been linked to a variety of skin disorders. To our knowledge, the prevalence of AITD has not been investigated in patients with HS. Read More

    Axillary Reconstruction for Hidradenitis Suppurativa with an Inner-Arm Transposition Flap Creating a Brachioplasty Effect.
    Arch Plast Surg 2017 May 22;44(3):228-233. Epub 2017 May 22.
    Department of Plastic and Reconstructive Surgery, St George's Healthcare NHS Trust, London, UK.
    Background: Hidradenitis suppurativa (HS) is a chronic skin condition that can affect any area with apocrine sweat glands and has the potential to involve multiple sites concurrently. Commonly affected sites include the axilla, groin, perineum and perianal areas. In this study we performed a literature review on the surgical methods for HS and describe an innovative technique for reconstructing axilla HS using an inner-arm transposition flap. Read More

    Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.
    Skin Appendage Disord 2017 May 21;3(2):95-110. Epub 2017 Mar 21.
    Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. Read More

    Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa.
    J Am Acad Dermatol 2017 May 24. Epub 2017 May 24.
    Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina. Electronic address:
    Background: Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by painful recurrent nodules and abscesses caused by chronic inflammation. Early events in the development of HS are believed to occur in the folliculopilosebaceous unit; however, the signaling pathways behind this mechanism are unknown. Sphingolipids, such as ceramide, are essential components of the skin and appendages and have important structural and signaling roles. Read More

    The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls.
    JAMA Dermatol 2017 May 24. Epub 2017 May 24.
    Department of Dermatology, Zealand University Hospital, Health Sciences Faculty, University of Copenhagen, Roskilde, Denmark.
    Importance: Although the pathogenesis of hidradenitis suppurativa (HS) remains enigmatic, several factors point to potential involvement of the cutaneous microbiome. Insight into the cutaneous microbiome in HS using next-generation sequencing may provide novel data on the microbiological diversity of the skin.

    Objective: To investigate the follicular skin microbiome in patients with HS and in healthy controls. Read More

    Hidradenitis suppurativa: epidemiological study of cases diagnosed at a dermatological reference center in the city of Bauru, in the Brazilian southeast State of São Paulo, between 2005 and 2015.
    An Bras Dermatol 2017 Mar-Apr;92(2):196-199
    Department of Dermatology, Instituto Lauro de Souza Lima (ILSL) - Bauru (SP), Brazil.
    Background:: Hidradenitis is a chronic inflammatory disease of the hair follicles. A treatment is necessary due to chronicity and psychological changes that patient present.

    Objective:: To investigate epidemiological aspects and elaborate a risk group profile, promote early diagnosis and contribute to the knowledge about the disease. Read More

    Major gaps in understanding and treatment of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):86-92
    Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
    Hidradenitis suppurativa (HS) is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. The disease is poorly understood and treatment is not satisfactory. In October 2016, the Canadian and United States Hidradenitis Suppurativa Foundations organized the inaugural Symposium on Hidradenitis Suppurativa Advances (SHSA) in Toronto, Canada. Read More

    Complications of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):79-85
    Department of Dermatology, University of California, San Francisco, USA.
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules and abscesses involving intertriginous areas. Repeated episodes of profound inflammation in HS can lead to a number of complications, causing significant morbidity and decreasing quality of life. Complications of HS may affect the skin alone or may have systemic impact. Read More

    Quality of life considerations and pain management in hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):75-78
    Deptartment of Dermatology, Zealand University Hospital, Roskilde, and Health Sciences Faculty, University of Copenhagen, Denmark.
    All skin diseases involve some element of stigmatization and psychosocial consequence for the individual patient, but few, if any, skin diseases can match the impact of hidradenitis suppurativa (HS) on the patient. The inflamed lesions progressing to noninflamed nodules and abscesses are not only perceived as unclean and stigmatizing by the patients, but also cause pain and scarring making this inflammatory skin disorder unique. It is obvious that the disease has a significant negative impact on the patients' quality of life (QOL). Read More

    A retrospective review of light- and laser-based management of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):67-74
    Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.
    Hidradenitis suppurativa (HS) is a chronic skin disease that is difficult to manage and often refractory to medical management. Light and laser therapies have been utilized in the field of dermatology to treat a variety of skin conditions, but more recently were studied in the management of HS. Usually performed as outpatient procedures with a low risk of complications, they offer several advantages to traditional cold knife surgical procedures. Read More

    Medical management of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):62-66
    Departments of Dermatology and Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA.
    Hidradenitis suppurativa is a chronic inflammatory disease of the folliculo-infundibular unit for which no individual treatment is uniformly effective. A wide array of therapies has been reported successful in the treatment of hidradenitis, although few high-quality clinical trials have been conducted. Comparing the effectiveness of different therapies has proven challenging due to heterogeneity and limited validation of outcome measures. Read More

    Topical management and wound care approaches for hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):58-61
    Department of Dermatology, University of Cincinnati, Ohio, USA.
    Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects the follicular unit in apocrine glandbearing skin, resulting in deep-seated nodules, sinus tracts, abscesses, and ultimately scarring. HS is a highly distressing condition, and has one of the highest impacts on quality of life compared to other dermatologic diseases. Various topical therapies have been described that may be used alone or in conjunction with systemic or physical modalities for HS. Read More

    Comorbidities of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):55-57
    Department of Dermatology, Harvard Medical School and Harvard Medical Faculty Physicians, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
    Hidradenitis suppurativa (HS) is an inflammatory skin disorder with many associated comorbidities, including obesity, metabolic syndrome, smoking, depression, arthritis, autoinflammatory syndromes, inflammatory bowel disease, and genetic syndromes. In addition, HS patients can suffer from a variety of diseases related to the chronic inflammatory nature of their HS such as cardiovascular disease and anemia. An understanding of these comorbidities and associations is essential for the management of HS, and routine screening for these entities should be considered in all HS patients. Read More

    Pathophysiology of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):47-54
    Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
    The pathophysiology of hidradenitis suppurativa (HS) is not well understood. Some of our knowledge comes from clinical and epidemiological observations, along with studies of the histopathology and immunohistochemistry of affected skin. More recently, cutaneous molecular studies and transcriptomic analyses have provided additional information regarding inflammatory processes. Read More

    Epidemiologic and clinical features of hidradenitis suppurativa.
    Semin Cutan Med Surg 2017 Jun;36(2):42-46
    Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
    Hidradenitis suppurativa (HS) is an inflammatory condition characterized by recurrent abscesses which may result in sinus tracts and dermal scarring. This article reviews current epidemiologic data on HS in diverse populations, including prevalence based on geography, age, gender, ethnicity, and details the spectrum of clinical features of hidradenitis suppurativa with discussion of disease severity and risk factors. Recently proposed HS diagnostic criteria are also presented. Read More

    Hidradenitis suppurativa, introduction.
    Semin Cutan Med Surg 2017 Jun;36(2):41
    Department of Dermatology, University of California, San Francisco, California, USA.
    Hidradenitis suppurativa (HS) is a prevalent and devastating inflammatory skin disease predominating in women and minorities. HS is characterized by painful recurrent abscesses, foul-smelling purulent drainage, sinus tract and fistula formation, and disfiguring scarring involving intertriginous body sites including the axillae, breasts, groin, and buttocks. Disease onset typically occurs in the second to fourth decades of life and is associated with significant impacts on physical and psychological well-being due to pain, shame, and isolation, leading to profound suffering and despair. Read More

    Ultrasound Evaluation as a Complementary Test in Hidradenitis Suppurativa: Proposal of a Standarized Report.
    Dermatol Surg 2017 May 22. Epub 2017 May 22.
    *Department of Dermatology, Hospital de Manises, Valencia, Spain;†Departments of Radiology and Dermatology, Institute for Diagnostic Imaging and Research of the Skin and Soft Tissues, Clinica Servet, Faculty of Medicine, University of Chile, Santiago, Chile;‡Department of Dermatology, Hospital Puerta del Hierro, Majahonda, Madrid, Spain;§Department of Dermatology, Virgen de las Nieves University Hospital, Granada, Spain;‖Department of Radiology, National Cancer Institute Fondazione Pascale, Naples, Italy;¶Department of Radiology, Università degli studi di Napoli, Naples, Italy;#Department of Dermatology, Roskilde Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark;**Department of Radiology, Affiliation Hospital das Clínicas da Faculdade de Medicina de São Paulo, Brazil;††Department of Medical Imaging, Rambam Health Care Centre, Haifa, Israel;‡‡Department of Radiology, IDIME Instituto de Imágenes Diagnósticas, Bogota, Colombia;§§Bard Cancer Center, New York, New York;‖‖Department of Dermatology, Clínica Universidad de Navarra, Madrid, Spain;¶¶Department of Radiodiagnosis, Central Hospital, South Central Railway, Telangana, India.
    Background: Staging and monitoring of patients with hidradenitis suppurativa (HS) have been traditionally based on clinical findings. However, the physical examination may show important limitations because of its poor sensitivity for differentiating between different lesion subtypes, and its low sensitivity to define the disease's activity.

    Objective: To develop a consensus ultrasound (US) report that could summarize the relevant anatomical characteristics and staging of patients considering the experience of radiologists and dermatologists working on imaging of HS. Read More

    Should Hidradenitis Suppurativa Be Included in Dermatoses Showing Koebnerization? Is It Friction or Fiction?
    Dermatology 2017 May 16. Epub 2017 May 16.
    Background: The etiology of hidradenitis suppurativa (HS) involves genetic and environmental factors. Well-established associated systemic factors are obesity, smoking, inflammation, and bacteria. Whether localized environmental factors such as friction and pressure may also play a causative role is still unclear. Read More

    A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.
    Nutrients 2017 May 15;9(5). Epub 2017 May 15.
    Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark.
    Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Read More

    Hidradenitis Suppurativa Is Associated with Familial Mediterranean Fever -A Population-Based Study.
    J Invest Dermatol 2017 May 9. Epub 2017 May 9.
    Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel; Siaal Research Center for Family Medicine and Primary Care, Division of Community Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

    Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States.
    JAMA Dermatol 2017 May 10. Epub 2017 May 10.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, New York.
    Importance: The true prevalence of hidradenitis suppurativa (HS) is unknown.

    Objective: To establish standardized overall and group-specific prevalence estimates for HS in the United States.

    Design, Setting, And Participants: This retrospective analysis included a demographically heterogeneous population-based sample of more than 48 million unique patients across all US census regions. Read More

    Hidradenitis Suppurativa, Intimate Partner Violence, and Sexual Assault.
    J Cutan Med Surg 2017 May 1:1203475417708167. Epub 2017 May 1.
    1 Department of Psychology, University of Windsor, Windsor, Ontario, Canada.
    Background: Sexual assault and intimate partner violence have never been examined in individuals with hidradenitis suppurativa. The research is important, because prior studies show higher incidences of intimate partner violence and sexual assault in individuals with disabilities, and hidradenitis suppurativa meets criteria for a disability.

    Objectives: The objective of the study is to examine whether individuals with hidradenitis suppurativa are at significantly higher risk of intimate partner violence and sexual assault compared with individuals who have acne, a recognised disability. Read More

    Biologics in patients with skin diseases.
    J Allergy Clin Immunol 2017 May;139(5):1423-1430
    Sunnybrook Health Sciences Centre and University of Toronto, Department of Medicine, Division of Dermatology, Toronto, Ontario, Canada. Electronic address:
    Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris. Read More

    [Diagnosis and treatment of hidradenitis suppurativa].
    Ugeskr Laeger 2017 May;179(18)
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined by recurrent nodules, tunnels and scarring involving the intertriginous regions. Although patients with HS present a distinct symptomatology with a subsequent impairment of quality of life, an overall diagnostic time of seven years has been reported. A better and broader understanding of this disease may potentially reduce the diagnostic delay. Read More

    Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment.
    Clin Cosmet Investig Dermatol 2017 19;10:105-115. Epub 2017 Apr 19.
    Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. Read More

    Non-surgical treatments for hidradenitis suppurativa: A systematic review.
    Ann Chir Plast Esthet 2017 Apr 27. Epub 2017 Apr 27.
    Department of plastic, reconstructive and aesthetic surgery, Rangueil hospital, 1, avenue Jean-Poulhès, 31059 Toulouse, France. Electronic address:
    Introduction: The management of hidradenitis suppurativa is multidisciplinary, involving general measures, medical treatment and surgery. Non-surgical treatments, often first-line procedures, mainly concern forms of low-to-moderate severity or, conversely, very severe forms in non-operable patients or those refusing surgery. While many treatments have been attempted, few randomized controlled trials have been conducted, so the choice of treatments is most often based on the personal experience of the clinicians. Read More

    Validation of a Case-Finding Algorithm for Hidradenitis Suppurativa Using Administrative Coding from a Clinical Database.
    Dermatology 2017 Apr 28. Epub 2017 Apr 28.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.
    Background: Requisite to the application of clinical databases for observational research in hidradenitis suppurativa (HS) is the identification of an accurate case cohort.

    Objective: To assess the validity of utilizing administrative codes to establish the HS cohort from a large clinical database.

    Methods: In this retrospective study using chart review as the reference standard, we calculated several estimates of the diagnostic accuracy of at least 1 ICD-9 code for HS. Read More

    Paradoxical psoriasiform reactions to anti-TNFα drugs in hidradenitis suppurativa.
    Br J Dermatol 2017 Apr 26. Epub 2017 Apr 26.
    Dermatology Department, University Hospital of Bordeaux, Bordeaux, France.
    Paradoxical psoriasiform reactions to anti-tumor necrosis factor α (TNFα) agents occur with an incidence of 0.3 to 5.6% in patients with inflammatory bowel diseases and rheumatic diseases(1) . Read More

    1 OF 32